Rockwell Medical, Inc. — Q3 2016 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2016. Unaudited consolidated results. Rockwell develops renal drug therapies and manufactures hemodialysis concentrates; nearly all reported product sales were concentrates and related ancillary products.
Financial performance
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Sales | $12.8 million | $14.4 million | $39.9 million | $41.2 million |
| Gross profit (margin) | $1.6 million (12.3%) | $2.5 million (17.4%) | $4.8 million (11.9%) | $6.9 million (16.7%) |
| Operating loss | $4.8 million | $2.6 million | $14.9 million | $9.0 million |
| Net loss | $4.6 million | $2.4 million | $14.7 million | $8.7 million |
| Loss per share, basic and diluted | $0.09 | $0.05 | $0.29 | $0.17 |
- For the first nine months, operating cash use was $13.0 million, compared with $13.5 million in 2015. Capital expenditures were $0.3 million. Cash and cash equivalents were $19.3 million at September 30; available-for-sale investments were $38.4 million, for combined cash and investments of about $57.7 million.
- Current assets were $79.8 million and working capital was $72.5 million. Current liabilities were $7.3 million. The company reported no long-term debt and no interest expense.
- Share-based compensation was $7.8 million for the first nine months and contributed to higher operating expenses. R&D expense rose to $4.6 million from $2.9 million, reflecting work on additional Triferic indications. SG&A increased to $15.1 million from $13.0 million, primarily due to equity compensation and legal expense.
Changes and management commentary
- Q3 sales fell 10.9% year over year; nine-month sales declined 3.2%. Management attributed Q3 weakness to lower domestic and international concentrate volumes and a completed third-party manufacturing contract. Year-to-date domestic concentrate revenue increased 2.5%, while international concentrate revenue fell 12.7%.
- Gross profit fell by $0.9 million in Q3 and $2.1 million year to date. Management cited higher drug-manufacturing and regulatory costs, including $0.3 million in value-added taxes related to the China license payment, along with lower sales volumes.
- Triferic sales were not material in the first nine months. Management said sales activity was expected to remain limited while it pursued transitional add-on Medicare reimbursement. The filing provides no quantified sales or earnings guidance.
- Rockwell received a $4 million upfront payment under its February 2016 Wanbang agreement for China rights to Triferic and Calcitriol; approximately $0.2 million was recognized as deferred license revenue in the first nine months. The agreement may provide up to $35 million in additional regulatory and revenue milestones over its term, plus product earnings, subject to conditions and approvals.
- In Q3, Rockwell entered an exclusive 10-year licensing and manufacturing-supply agreement with ARAM Medical for Saudi Arabia and other Middle Eastern markets. Commercial sales depend on regulatory approval; the filing does not disclose the licensing fee amount.
- Management said it believed resources were adequate for planned operations, inventory, and development spending, and expected positive operating cash flow when drug sales become significant. It also anticipated higher inventory and receivables as drug sales grow. These are management expectations, not assured outcomes.
Risks, contingencies, and unusual items
- Baxter dispute: Arbitration concerns allegations by both parties of breaches of the concentrate distribution agreement, including unpaid receivables, a disputed West Coast facility fee, and other contract claims. Baxter sought termination rights, a portion of its upfront fee, injunctive relief, and unspecified damages; Rockwell denied the claims and counterclaimed. Rockwell reported that Baxter paid $3.6 million in October 2016 against approximately $4.1 million of past-due receivables at September 30.
- Rockwell asserted Baxter failed to meet minimum purchase requirements for the contract year ending October 2, 2016, and notified Baxter that its distribution rights had become non-exclusive. Baxter disputed the alleged breach; the arbitration will determine the outcome. A loss or change of the distribution relationship could disrupt sales, margins, and customer access.
- The filing describes potential refunds under the Baxter agreement, including 50% of the $20 million upfront fee, plus any facility fee paid, if a specified refund-trigger event occurs before December 31, 2016. Rockwell had not reserved for the Baxter receivable claim, citing its view that Baxter’s claims or defenses lacked factual support.
- Calcitriol commercial readiness had been delayed after a contract manufacturer identified a stability issue with an inactive ingredient. Rockwell said it believed the issue was resolved, but the FDA had requested additional stability data and further batches were being manufactured before commercial release.
- Available-for-sale bond funds were exposed to interest-rate-related fair-value changes. Management did not believe a hypothetical 100-basis-point rate change would materially affect portfolio value. The filing reported disclosure controls effective at a reasonable-assurance level and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Developments and outcome of the Baxter arbitration, including the receivable balance, distribution exclusivity, potential damages or refunds, and any effect on concentrate customers and sales.
- Whether Triferic obtains transitional Medicare reimbursement and achieves meaningful commercial adoption; the timing of Calcitriol stability-data acceptance and commercial release.
- Cash burn, working-capital needs, and the ability to fund ongoing operations if drug revenue or licensing milestones are delayed.
- Regulatory approvals, milestones, and actual commercial progress under the Wanbang and ARAM agreements; milestone amounts are conditional and not guaranteed.